Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
Abstract Immune checkpoint inhibitors (ICIs) have made a breakthrough in the treatment of different types of tumors, leading to improvement in survival, even in patients with advanced cancers. Despite the good clinical results, a certain percentage of patients do not respond to this kind of immunoth...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMC
2020-11-01
|
| Rangatū: | Journal of Experimental & Clinical Cancer Research |
| Ngā marau: | |
| Urunga tuihono: | http://link.springer.com/article/10.1186/s13046-020-01721-9 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|